| Disease ID | Disease name | Source of annotation with AKT1 | OMIM link | Number of associated genes | genes |
|---|---|---|---|---|---|
| 181500 | SCHIZOPHRENIA | OMIM | link to OMIM | 17 | COMT, DISC2, MTHFR, DISC1, SYN2, MC4R, DAO, AKT1, HTR2A, APOL2, APOL4, SETD1A, CHI3L1, DTNBP1, RTN4R, DRD3, DAOA |
| 114480 | BREAST CANCER | OMIM, HUMSAVAR | link to OMIM | 27 | RB1CC1, ESR1, NBN, PALB2, SLC22A18, BRIP1, BCPR, CASP8, FAM175A, TSG101, CHEK2, BARD1, TP53, AKT1, BRCA1, PIK3CA, PHB, PPM1D, NQO2, ATM, RAD51, BRCA2, CDH1, XRCC3, HMMR, KRAS, RAD54L |
| 176920 | PROTEUS SYNDROME | OMIM, HUMSAVAR | link to OMIM | 1 | AKT1 |
| PS158350 | COWDEN DISEASE | ClinVar, OMIM, HUMSAVAR | link to OMIM | 7 | AKT1, PTEN, SEC23B, SDHB, PIK3CA, KLLN, SDHD |
| 114500 | COLORECTAL CANCER | OMIM | link to OMIM | 30 | TLR4, RAD54B, PTPRJ, TP53, EP300, PTPN12, ODC1, FLCN, TLR2, BAX, PLA2G2A, AURKA, NRAS, APC, MCC, TRIM28, MLH3, AKT1, MT-CO1, AXIN2, CTNNB1, PDGFRL, PIK3CA, KAT5, DCC, BRAF, CCND1, FGFR3, DLC1, BUB1B |
| 167000 | OVARIAN CANCER | OMIM | link to OMIM | 9 | AKT1, PARK2, CTNNB1, CDH1, BRCA1, RRAS2, PIK3CA, OPCML, SEPT9 |
Download the gene annotation in CSV format
| KEGG pathway | KEGG ID | KEGG IC |
|---|---|---|
| Melanoma | hsa05218 | 6.56 |
| Platelet activation | hsa04611 | 5.66 |
| Progesterone-mediated oocyte maturation | hsa04914 | 6.18 |
| Small cell lung cancer | hsa05222 | 6.17 |
| Pancreatic cancer | hsa05212 | 6.56 |
| Endometrial cancer | hsa05213 | 6.81 |
| Colorectal cancer | hsa05210 | 6.52 |
| MAPK signaling pathway | hsa04010 | 4.63 |
| Jak-STAT signaling pathway | hsa04630 | 5.44 |
| Signaling pathways regulating pluripotency of stem cells | hsa04550 | 5.6 |
| Glioma | hsa05214 | 6.66 |
| Prostate cancer | hsa05215 | 6.11 |
| Tight junction | hsa04530 | 5.53 |
| Neurotrophin signaling pathway | hsa04722 | 5.78 |
| Cholinergic synapse | hsa04725 | 5.88 |
| Choline metabolism in cancer | hsa05231 | 6.09 |
| FoxO signaling pathway | hsa04068 | 5.63 |
| Osteoclast differentiation | hsa04380 | 5.64 |
| HIF-1 signaling pathway | hsa04066 | 5.9 |
| Dopaminergic synapse | hsa04728 | 5.69 |
| Chemokine signaling pathway | hsa04062 | 5.19 |
| Adipocytokine signaling pathway | hsa04920 | 6.6 |
| Focal adhesion | hsa04510 | 4.92 |
| ErbB signaling pathway | hsa04012 | 6.15 |
| Chagas disease (American trypanosomiasis) | hsa05142 | 5.99 |
| cGMP-PKG signaling pathway | hsa04022 | 5.32 |
| Epstein-Barr virus infection | hsa05169 | 4.97 |
| Toxoplasmosis | hsa05145 | 5.71 |
| Influenza A | hsa05164 | 5.21 |
| Apoptosis | hsa04210 | 6.23 |
| HTLV-I infection | hsa05166 | 4.59 |
| Hepatitis C | hsa05160 | 5.68 |
| Hepatitis B | hsa05161 | 5.52 |
| Measles | hsa05162 | 5.6 |
| B cell receptor signaling pathway | hsa04662 | 6.52 |
| Renal cell carcinoma | hsa05211 | 6.6 |
| VEGF signaling pathway | hsa04370 | 6.77 |
| Proteoglycans in cancer | hsa05205 | 5.02 |
| Estrogen signaling pathway | hsa04915 | 6.11 |
| Toll-like receptor signaling pathway | hsa04620 | 6.0 |
| Pathways in cancer | hsa05200 | 3.98 |
| T cell receptor signaling pathway | hsa04660 | 6.01 |
| Fc gamma R-mediated phagocytosis | hsa04666 | 6.21 |
| Rap1 signaling pathway | hsa04015 | 4.97 |
| Ras signaling pathway | hsa04014 | 4.9 |
| Fc epsilon RI signaling pathway | hsa04664 | 6.6 |
| cAMP signaling pathway | hsa04024 | 5.05 |
| Acute myeloid leukemia | hsa05221 | 6.74 |
| Chronic myeloid leukemia | hsa05220 | 6.48 |
| TNF signaling pathway | hsa04668 | 5.96 |
| Thyroid hormone signaling pathway | hsa04919 | 5.82 |
| AMPK signaling pathway | hsa04152 | 5.8 |
| mTOR signaling pathway | hsa04150 | 6.72 |
| PI3K-Akt signaling pathway | hsa04151 | 4.21 |
| Carbohydrate digestion and absorption | hsa04973 | 7.28 |
| Non-small cell lung cancer | hsa05223 | 6.88 |
| Insulin signaling pathway | hsa04910 | 5.55 |
| Tuberculosis | hsa05152 | 5.17 |
| Non-alcoholic fatty liver disease (NAFLD) | hsa04932 | 5.51 |
| Central carbon metabolism in cancer | hsa05230 | 6.7 |
| Adrenergic signaling in cardiomyocytes | hsa04261 | 5.44 |
| Prolactin signaling pathway | hsa04917 | 6.6 |
| REACTOME pathway | REACTOME ID | REACTOME IC |
|---|---|---|
| GPVI-mediated activation cascade | R-HSA-114604 | 7.18 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 4.62 |
| GAB1 signalosome | R-HSA-180292 | 6.31 |
| Developmental Biology | R-HSA-1266738 | 3.48 |
| Generic Transcription Pathway | R-HSA-212436 | 3.86 |
| IRS-mediated signalling | R-HSA-112399 | 4.87 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 9.08 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 6.56 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 4.7 |
| Activation of BH3-only proteins | R-HSA-114452 | 8.34 |
| Translocation of GLUT4 to the plasma membrane | R-HSA-1445148 | 6.77 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 9.28 |
| Signaling by EGFR | R-HSA-177929 | 4.59 |
| Vesicle-mediated transport | R-HSA-5653656 | 4.33 |
| Integrin alphaIIb beta3 signaling | R-HSA-354192 | 8.23 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 6.37 |
| DAP12 interactions | R-HSA-2172127 | 4.56 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.71 |
| Signaling by ERBB2 | R-HSA-1227986 | 4.66 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 8.28 |
| PI3K/AKT activation | R-HSA-198203 | 6.32 |
| Immune System | R-HSA-168256 | 2.37 |
| eNOS activation | R-HSA-203615 | 9.98 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 6.37 |
| Downstream signal transduction | R-HSA-186763 | 4.65 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 9.81 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 4.95 |
| CTLA4 inhibitory signaling | R-HSA-389513 | 8.52 |
| CD28 co-stimulation | R-HSA-389356 | 7.98 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 8.59 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 4.71 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 4.03 |
| Innate Immune System | R-HSA-168249 | 3.17 |
| Signaling by SCF-KIT | R-HSA-1433557 | 4.73 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 5.36 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 7.73 |
| NGF signalling via TRKA from the plasma membrane | R-HSA-187037 | 4.51 |
| Signaling by Wnt | R-HSA-195721 | 4.79 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 9.28 |
| Signaling by FGFR2 | R-HSA-5654738 | 4.68 |
| Signaling by FGFR1 | R-HSA-5654736 | 4.69 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 6.37 |
| PI3K Cascade | R-HSA-109704 | 6.68 |
| PKB-mediated events | R-HSA-109703 | 7.66 |
| KSRP destabilizes mRNA | R-HSA-450604 | 8.89 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 8.66 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 6.73 |
| Programmed Cell Death | R-HSA-5357801 | 5.65 |
| IGF1R signaling cascade | R-HSA-2428924 | 4.85 |
| deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 7.59 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 4.85 |
| Signaling by Insulin receptor | R-HSA-74752 | 4.73 |
| Disease | R-HSA-1643685 | 3.33 |
| Insulin receptor signalling cascade | R-HSA-74751 | 4.85 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 9.98 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 4.71 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 6.37 |
| Gene Expression | R-HSA-74160 | 2.72 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 6.37 |
| Butyrate Response Factor 1 (BRF1) destabilizes mRNA | R-HSA-450385 | 8.89 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 5.59 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 6.73 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 6.56 |
| Signaling by VEGF | R-HSA-194138 | 4.66 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 7.4 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 6.37 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 4.71 |
| Regulation of beta-cell development | R-HSA-186712 | 7.98 |
| mTOR signalling | R-HSA-165159 | 7.7 |
| Signaling by PDGF | R-HSA-186797 | 4.53 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 9.66 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 4.85 |
| Metabolism | R-HSA-1430728 | 2.34 |
| Signaling by ERBB4 | R-HSA-1236394 | 4.7 |
| Adaptive Immune System | R-HSA-1280218 | 3.19 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 7.77 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 6.37 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 5.15 |
| Diseases of signal transduction | R-HSA-5663202 | 4.89 |
| Metabolism of nitric oxide | R-HSA-202131 | 8.81 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 8.4 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 10.98 |
| Costimulation by the CD28 family | R-HSA-388841 | 6.56 |
| Signaling by FGFR4 | R-HSA-5654743 | 4.69 |
| Signaling by FGFR3 | R-HSA-5654741 | 4.69 |
| Signaling by FGFR | R-HSA-190236 | 4.67 |
| GPCR downstream signaling | R-HSA-388396 | 3.07 |
| eNOS activation and regulation | R-HSA-203765 | 8.81 |
| Membrane Trafficking | R-HSA-199991 | 5.26 |
| DAP12 signaling | R-HSA-2424491 | 4.64 |
| Signalling by NGF | R-HSA-166520 | 4.23 |
| Signaling by GPCR | R-HSA-372790 | 2.68 |
| G-protein beta:gamma signalling | R-HSA-397795 | 7.31 |
| Signal Transduction | R-HSA-162582 | 1.78 |
| Hemostasis | R-HSA-109582 | 3.98 |
| Apoptosis | R-HSA-109581 | 5.68 |
| GO term | GO ID | GO IC |
|---|---|---|
| purine ribonucleoside triphosphate binding | GO:0035639 | 2.22 |
| protein kinase C binding | GO:0005080 | 5.83 |
| GTPase activating protein binding | GO:0032794 | 7.1 |
| enzyme binding | GO:0019899 | 2.27 |
| binding | GO:0005488 | 0.18 |
| ion binding | GO:0043167 | 1.36 |
| heterocyclic compound binding | GO:1901363 | 1.06 |
| purine nucleoside binding | GO:0001883 | 2.22 |
| nucleoside binding | GO:0001882 | 2.21 |
| anion binding | GO:0043168 | 4.17 |
| molecular function regulator | GO:0098772 | 2.51 |
| kinase binding | GO:0019900 | 3.32 |
| phospholipid binding | GO:0005543 | 3.91 |
| ribonucleoside binding | GO:0032549 | 2.22 |
| nucleotide binding | GO:0000166 | 1.96 |
| protein serine/threonine kinase activity | GO:0004674 | 3.64 |
| transferase activity | GO:0016740 | 1.95 |
| phosphatidylinositol-3,4-bisphosphate binding | GO:0043325 | 6.74 |
| protein serine/threonine/tyrosine kinase activity | GO:0004712 | 6.07 |
| nucleoside phosphate binding | GO:1901265 | 1.96 |
| protein kinase activity | GO:0004672 | 3.27 |
| purine nucleotide binding | GO:0017076 | 2.19 |
| identical protein binding | GO:0042802 | 2.63 |
| kinase activity | GO:0016301 | 2.93 |
| 14-3-3 protein binding | GO:0071889 | 6.65 |
| enzyme regulator activity | GO:0030234 | 2.85 |
| nitric-oxide synthase regulator activity | GO:0030235 | 7.79 |
| lipid binding | GO:0008289 | 3.26 |
| protein kinase binding | GO:0019901 | 3.44 |
| catalytic activity | GO:0003824 | 1.05 |
| protein phosphatase binding | GO:0019903 | 4.93 |
| phosphatase binding | GO:0019902 | 4.63 |
| phosphatidylinositol phosphate binding | GO:1901981 | 5.05 |
| phosphatidylinositol-3,4,5-trisphosphate binding | GO:0005547 | 6.21 |
| phosphotransferase activity, alcohol group as acceptor | GO:0016773 | 3.08 |
| protein phosphatase 2A binding | GO:0051721 | 6.41 |
| small molecule binding | GO:0036094 | 1.89 |
| adenyl nucleotide binding | GO:0030554 | 2.4 |
| carbohydrate derivative binding | GO:0097367 | 2.03 |
| organic cyclic compound binding | GO:0097159 | 1.05 |
| phosphatidylinositol binding | GO:0035091 | 4.47 |
| adenyl ribonucleotide binding | GO:0032559 | 2.41 |
| ATP binding | GO:0005524 | 2.43 |
| protein binding | GO:0005515 | 0.46 |
| transferase activity, transferring phosphorus-containing groups | GO:0016772 | 2.77 |
| purine ribonucleotide binding | GO:0032555 | 2.2 |
| purine ribonucleoside binding | GO:0032550 | 2.22 |
| ribonucleotide binding | GO:0032553 | 2.19 |